RegeneRx Biopharmaceuticals, Inc. (OTCMKTS:RGRX) Short Interest Update

RegeneRx Biopharmaceuticals, Inc. (OTCMKTS:RGRXGet Rating) saw a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 89,200 shares, a decline of 35.4% from the March 31st total of 138,000 shares. Based on an average trading volume of 108,600 shares, the days-to-cover ratio is presently 0.8 days.

Shares of RGRX opened at $0.16 on Friday. RegeneRx Biopharmaceuticals has a 1 year low of $0.10 and a 1 year high of $0.45. The firm has a fifty day moving average of $0.19 and a 200-day moving average of $0.19.

RegeneRx Biopharmaceuticals Company Profile (Get Rating)

RegeneRx Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue.

Featured Articles

Receive News & Ratings for RegeneRx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.